A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer

Rossella Lauria, Ettore Ferrari, Sergio Tramontana, Alessandro Morabito, Francesco Perrone, Antonio Maffeo, Roberto Fiorentino, Gennaro Casella, Francesco Iodice, Paolo Ricchi, Chiara Carlomagno, Elisa Varriale, Giuseppe De Placido, Sabino De Placido, Angelo Raffaele Bianco, Sandro Pignata

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of the study was to determine the maximum tolerated dose (MTD) of epirubicin combined with a fixed dose of paclitaxel, without and with support of filgrastim, in patients with platinum resistant or refractory ovarian cancer. Paclitaxel (150 mg/m2) and epirubicin (starting dose 90 mg/m2, 15 mg/m2 escalation per level) were given on day 1, every 28 days for 4-6 cycles. Filgrastim (F) (5 μg/kg/die) was given in case of grade 4 leukopenia (levels without support) or from day 4 up to leukocyte count > 10,000/mm3 after nadir (levels with support). Cohorts of 3 patients were enrolled at each level and further 3 patients were planned if 1 or 2 unacceptable toxic events (UTE) were registered. MTD was determined first without and then with filgrastim. Four levels were studied (90, 90+F, 105+F, 120+F) with 4, 6, 5 and 4 patients enrolled, respectively. UTE (grade 4 neutropenia) were observed in 3 patients at level 1. Thus, 90 mg/m2 was the MTD for epirubicin without filgrastim. MTD of epirubicin with filgrastim was not reached at 120 mg/m2. Hematological toxicity was mild. Grade 3 mucositis was reported in 1 patient. Among the 14 patients with measurable or evaluable disease, 3 objective responses were observed (1 complete and 2 partial) for an overall response rate of 21.4%. The combination of paclitaxel 150 mg/m2 and epirubicin at 120 mg/m2 with filgrastim is a feasible therapy. Grade 4 leukopenia is the dose limiting toxicity using epirubicin at 90 mg/m2 without filgrastim.

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalOncology
Volume56
Issue number4
DOIs
Publication statusPublished - May 1999

Fingerprint

Epirubicin
Paclitaxel
Platinum
Ovarian Neoplasms
Maximum Tolerated Dose
Poisons
Leukopenia
Therapeutics
Mucositis
Filgrastim
Neutropenia
Leukocyte Count

Keywords

  • Chemotherapy
  • Ovarian cancer
  • Second-line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. / Lauria, Rossella; Ferrari, Ettore; Tramontana, Sergio; Morabito, Alessandro; Perrone, Francesco; Maffeo, Antonio; Fiorentino, Roberto; Casella, Gennaro; Iodice, Francesco; Ricchi, Paolo; Carlomagno, Chiara; Varriale, Elisa; De Placido, Giuseppe; De Placido, Sabino; Bianco, Angelo Raffaele; Pignata, Sandro.

In: Oncology, Vol. 56, No. 4, 05.1999, p. 267-273.

Research output: Contribution to journalArticle

Lauria, R, Ferrari, E, Tramontana, S, Morabito, A, Perrone, F, Maffeo, A, Fiorentino, R, Casella, G, Iodice, F, Ricchi, P, Carlomagno, C, Varriale, E, De Placido, G, De Placido, S, Bianco, AR & Pignata, S 1999, 'A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer', Oncology, vol. 56, no. 4, pp. 267-273. https://doi.org/10.1159/000011977
Lauria, Rossella ; Ferrari, Ettore ; Tramontana, Sergio ; Morabito, Alessandro ; Perrone, Francesco ; Maffeo, Antonio ; Fiorentino, Roberto ; Casella, Gennaro ; Iodice, Francesco ; Ricchi, Paolo ; Carlomagno, Chiara ; Varriale, Elisa ; De Placido, Giuseppe ; De Placido, Sabino ; Bianco, Angelo Raffaele ; Pignata, Sandro. / A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. In: Oncology. 1999 ; Vol. 56, No. 4. pp. 267-273.
@article{885fafac1ab34d55872d685d56acf594,
title = "A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer",
abstract = "The aim of the study was to determine the maximum tolerated dose (MTD) of epirubicin combined with a fixed dose of paclitaxel, without and with support of filgrastim, in patients with platinum resistant or refractory ovarian cancer. Paclitaxel (150 mg/m2) and epirubicin (starting dose 90 mg/m2, 15 mg/m2 escalation per level) were given on day 1, every 28 days for 4-6 cycles. Filgrastim (F) (5 μg/kg/die) was given in case of grade 4 leukopenia (levels without support) or from day 4 up to leukocyte count > 10,000/mm3 after nadir (levels with support). Cohorts of 3 patients were enrolled at each level and further 3 patients were planned if 1 or 2 unacceptable toxic events (UTE) were registered. MTD was determined first without and then with filgrastim. Four levels were studied (90, 90+F, 105+F, 120+F) with 4, 6, 5 and 4 patients enrolled, respectively. UTE (grade 4 neutropenia) were observed in 3 patients at level 1. Thus, 90 mg/m2 was the MTD for epirubicin without filgrastim. MTD of epirubicin with filgrastim was not reached at 120 mg/m2. Hematological toxicity was mild. Grade 3 mucositis was reported in 1 patient. Among the 14 patients with measurable or evaluable disease, 3 objective responses were observed (1 complete and 2 partial) for an overall response rate of 21.4{\%}. The combination of paclitaxel 150 mg/m2 and epirubicin at 120 mg/m2 with filgrastim is a feasible therapy. Grade 4 leukopenia is the dose limiting toxicity using epirubicin at 90 mg/m2 without filgrastim.",
keywords = "Chemotherapy, Ovarian cancer, Second-line",
author = "Rossella Lauria and Ettore Ferrari and Sergio Tramontana and Alessandro Morabito and Francesco Perrone and Antonio Maffeo and Roberto Fiorentino and Gennaro Casella and Francesco Iodice and Paolo Ricchi and Chiara Carlomagno and Elisa Varriale and {De Placido}, Giuseppe and {De Placido}, Sabino and Bianco, {Angelo Raffaele} and Sandro Pignata",
year = "1999",
month = "5",
doi = "10.1159/000011977",
language = "English",
volume = "56",
pages = "267--273",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer

AU - Lauria, Rossella

AU - Ferrari, Ettore

AU - Tramontana, Sergio

AU - Morabito, Alessandro

AU - Perrone, Francesco

AU - Maffeo, Antonio

AU - Fiorentino, Roberto

AU - Casella, Gennaro

AU - Iodice, Francesco

AU - Ricchi, Paolo

AU - Carlomagno, Chiara

AU - Varriale, Elisa

AU - De Placido, Giuseppe

AU - De Placido, Sabino

AU - Bianco, Angelo Raffaele

AU - Pignata, Sandro

PY - 1999/5

Y1 - 1999/5

N2 - The aim of the study was to determine the maximum tolerated dose (MTD) of epirubicin combined with a fixed dose of paclitaxel, without and with support of filgrastim, in patients with platinum resistant or refractory ovarian cancer. Paclitaxel (150 mg/m2) and epirubicin (starting dose 90 mg/m2, 15 mg/m2 escalation per level) were given on day 1, every 28 days for 4-6 cycles. Filgrastim (F) (5 μg/kg/die) was given in case of grade 4 leukopenia (levels without support) or from day 4 up to leukocyte count > 10,000/mm3 after nadir (levels with support). Cohorts of 3 patients were enrolled at each level and further 3 patients were planned if 1 or 2 unacceptable toxic events (UTE) were registered. MTD was determined first without and then with filgrastim. Four levels were studied (90, 90+F, 105+F, 120+F) with 4, 6, 5 and 4 patients enrolled, respectively. UTE (grade 4 neutropenia) were observed in 3 patients at level 1. Thus, 90 mg/m2 was the MTD for epirubicin without filgrastim. MTD of epirubicin with filgrastim was not reached at 120 mg/m2. Hematological toxicity was mild. Grade 3 mucositis was reported in 1 patient. Among the 14 patients with measurable or evaluable disease, 3 objective responses were observed (1 complete and 2 partial) for an overall response rate of 21.4%. The combination of paclitaxel 150 mg/m2 and epirubicin at 120 mg/m2 with filgrastim is a feasible therapy. Grade 4 leukopenia is the dose limiting toxicity using epirubicin at 90 mg/m2 without filgrastim.

AB - The aim of the study was to determine the maximum tolerated dose (MTD) of epirubicin combined with a fixed dose of paclitaxel, without and with support of filgrastim, in patients with platinum resistant or refractory ovarian cancer. Paclitaxel (150 mg/m2) and epirubicin (starting dose 90 mg/m2, 15 mg/m2 escalation per level) were given on day 1, every 28 days for 4-6 cycles. Filgrastim (F) (5 μg/kg/die) was given in case of grade 4 leukopenia (levels without support) or from day 4 up to leukocyte count > 10,000/mm3 after nadir (levels with support). Cohorts of 3 patients were enrolled at each level and further 3 patients were planned if 1 or 2 unacceptable toxic events (UTE) were registered. MTD was determined first without and then with filgrastim. Four levels were studied (90, 90+F, 105+F, 120+F) with 4, 6, 5 and 4 patients enrolled, respectively. UTE (grade 4 neutropenia) were observed in 3 patients at level 1. Thus, 90 mg/m2 was the MTD for epirubicin without filgrastim. MTD of epirubicin with filgrastim was not reached at 120 mg/m2. Hematological toxicity was mild. Grade 3 mucositis was reported in 1 patient. Among the 14 patients with measurable or evaluable disease, 3 objective responses were observed (1 complete and 2 partial) for an overall response rate of 21.4%. The combination of paclitaxel 150 mg/m2 and epirubicin at 120 mg/m2 with filgrastim is a feasible therapy. Grade 4 leukopenia is the dose limiting toxicity using epirubicin at 90 mg/m2 without filgrastim.

KW - Chemotherapy

KW - Ovarian cancer

KW - Second-line

UR - http://www.scopus.com/inward/record.url?scp=0033006384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033006384&partnerID=8YFLogxK

U2 - 10.1159/000011977

DO - 10.1159/000011977

M3 - Article

VL - 56

SP - 267

EP - 273

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -